Global Heparin Sodium Market

Heparin Sodium Comprehensive Study by Type (Unfractionated Heparin, Low Molecular Weight Heparin, Modified Heparin, Heparinoids), Application (Venous Thromboembolism, Complications of Pregnancy, Cardioversion of Atrial Fibrillation/Flutter, Others) Players and Region - Global Market Outlook to 2030

Heparin Sodium Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 3.3%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Heparin Sodium Market Overview:
The sodium salt of sulfated glycosaminoglycans is Heparin sodium and exist as a mixture of heterogeneous molecules different in molecular weights that retains a combination of activities against various factors of the blood clotting cascade. It is present in mammalian tissues & is typically obtained from the intestinal mucosa or other suitable tissues of domestic mammals used for food. It is an anticoagulant (blood thinner), prevents the formation of blood clots. It is used to treat as well as prevent blood clots in the veins, arteries, or lung, as well. Also, it is also before surgery to decrease the risk of blood clots. It comprised of polymers of alternating derivatives of α-D-glucosamido (O-sulfated, N-sulfated, or N-acetylated) & O-sulfated uronic acid (α-L-iduronic acid or β-D-glucuronic acid). Growing incidences of thrombosis is likely to impel the global Heparin sodium market growth during the forecasted period. As per latest study released by AMA Research, the Global Heparin Sodium market is expected to see growth rate of 3.3%

AttributesDetails
Study Period2018-2030
Base Year2023
Forecast Period2024-2030
Historical Period2018-2023
UnitValue (USD Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


Market Growth Drivers:
Growing incidences of thrombosis, Increasing government funding to healthcare facilities improvement and Increasing awareness about the availability of such treatment options among the patient population

Challenges:
Strict government regulations

Restraints:
Many cases of Adulterated Heparin

Opportunities:
Growing medical needs in emerging economies

Competitive Landscape:
The key manufacturers are targeting the innovations of the products with better quality, and better technical characteristics, and also assist in providing and humanizing the after-sale service to the consumers. The key players are probable to keep a stronghold on the market over the anticipated period. The key players are accepting strategic decisions and are thinking about mergers and acquisitions to maintain their presence in the market
Some of the key players profiled in the report are Pfizer Inc. (United States), Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (China), Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. (China), Bioiberica S.A.U. (Spain), OPOCRIN SPA (Italy), Yantai Dongcheng Pharmaceutical Group Co., Ltd. (China), Baxter International Inc. (United States), Aspen Holdings (The Netherlands), Sanofi-Aventis U.S. LLC (United States) and Sichuan Deebio Pharmaceutical Co., Ltd. (China). Additionally, following companies can also be profiled that are part of our coverage like Yantai Dongcheng Pharmaceutical Group Co., Ltd. (China), Changzhou Qianhong Bio-pharma Co., Ltd. (China) and Shenzhen Techdow Pharmaceutical Co., Ltd (China). Analyst at AMA Research see Chinese and United States Vendors to retain maximum share of Global Heparin Sodium market by 2030.

Latest Market Insights:
On February 21, 2023, Fresenius Kabi announced the acquisition of APP Pharmaceuticals, a leading provider of generic injectable drugs, including Heparin Sodium.

On November 14, 2023, Samsung Biologics announced a partnership with China's CSPC Pharmaceutical Group to develop and manufacture biosimilars, including Heparin Sodium.

"The United States Food and Drug Administration (FDA) is the regulatory body for heparin in United States and has been alerting healthcare providers of a change to the United States Pharmacopeia (USP) monograph for heparin, effective October 1, 2009. The United States Pharmacopeia (USP) has newly published updated compendial test methods for heparin sodium USP to contain the two screening tests previously posted on FDA’s website. Effective immediately, in accord with section 501(b) of the FD&C Act, all heparin sodium USP must meet compendial requirements as specified by the FDA."

What Can be Explored with the Heparin Sodium Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Heparin Sodium Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Heparin Sodium
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Heparin Sodium market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Heparin Sodium market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Heparin Sodium manufacturers, Raw material suppliers, Pharmaceutical Industry, Industry associations and government organisations and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Type
  • Unfractionated Heparin
  • Low Molecular Weight Heparin
  • Modified Heparin
  • Heparinoids
By Application
  • Venous Thromboembolism
  • Complications of Pregnancy
  • Cardioversion of Atrial Fibrillation/Flutter
  • Others
By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing incidences of thrombosis
      • 3.2.2. Increasing government funding to healthcare facilities improvement
      • 3.2.3. Increasing awareness about the availability of such treatment options among the patient population
    • 3.3. Market Challenges
      • 3.3.1. Strict government regulations
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Heparin Sodium, by Type, Application and Region (value, volume and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Heparin Sodium (Value)
      • 5.2.1. Global Heparin Sodium by: Type (Value)
        • 5.2.1.1. Unfractionated Heparin
        • 5.2.1.2. Low Molecular Weight Heparin
        • 5.2.1.3. Modified Heparin
        • 5.2.1.4. Heparinoids
      • 5.2.2. Global Heparin Sodium by: Application (Value)
        • 5.2.2.1. Venous Thromboembolism
        • 5.2.2.2. Complications of Pregnancy
        • 5.2.2.3. Cardioversion of Atrial Fibrillation/Flutter
        • 5.2.2.4. Others
      • 5.2.3. Global Heparin Sodium Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
    • 5.3. Global Heparin Sodium (Volume)
      • 5.3.1. Global Heparin Sodium by: Type (Volume)
        • 5.3.1.1. Unfractionated Heparin
        • 5.3.1.2. Low Molecular Weight Heparin
        • 5.3.1.3. Modified Heparin
        • 5.3.1.4. Heparinoids
      • 5.3.2. Global Heparin Sodium by: Application (Volume)
        • 5.3.2.1. Venous Thromboembolism
        • 5.3.2.2. Complications of Pregnancy
        • 5.3.2.3. Cardioversion of Atrial Fibrillation/Flutter
        • 5.3.2.4. Others
      • 5.3.3. Global Heparin Sodium Region
        • 5.3.3.1. South America
          • 5.3.3.1.1. Brazil
          • 5.3.3.1.2. Argentina
          • 5.3.3.1.3. Rest of South America
        • 5.3.3.2. Asia Pacific
          • 5.3.3.2.1. China
          • 5.3.3.2.2. Japan
          • 5.3.3.2.3. India
          • 5.3.3.2.4. South Korea
          • 5.3.3.2.5. Taiwan
          • 5.3.3.2.6. Australia
          • 5.3.3.2.7. Rest of Asia-Pacific
        • 5.3.3.3. Europe
          • 5.3.3.3.1. Germany
          • 5.3.3.3.2. France
          • 5.3.3.3.3. Italy
          • 5.3.3.3.4. United Kingdom
          • 5.3.3.3.5. Netherlands
          • 5.3.3.3.6. Rest of Europe
        • 5.3.3.4. MEA
          • 5.3.3.4.1. Middle East
          • 5.3.3.4.2. Africa
        • 5.3.3.5. North America
          • 5.3.3.5.1. United States
          • 5.3.3.5.2. Canada
          • 5.3.3.5.3. Mexico
    • 5.4. Global Heparin Sodium (Price)
      • 5.4.1. Global Heparin Sodium by: Type (Price)
  • 6. Heparin Sodium: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Pfizer Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (China)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. (China)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Bioiberica S.A.U. (Spain)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. OPOCRIN SPA (Italy)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Yantai Dongcheng Pharmaceutical Group Co., Ltd. (China)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Baxter International Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Aspen Holdings (The Netherlands)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Sanofi-Aventis U.S. LLC (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Sichuan Deebio Pharmaceutical Co., Ltd. (China)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Heparin Sodium Sale, by Type, Application and Region (value, volume and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Heparin Sodium (Value)
      • 7.2.1. Global Heparin Sodium by: Type (Value)
        • 7.2.1.1. Unfractionated Heparin
        • 7.2.1.2. Low Molecular Weight Heparin
        • 7.2.1.3. Modified Heparin
        • 7.2.1.4. Heparinoids
      • 7.2.2. Global Heparin Sodium by: Application (Value)
        • 7.2.2.1. Venous Thromboembolism
        • 7.2.2.2. Complications of Pregnancy
        • 7.2.2.3. Cardioversion of Atrial Fibrillation/Flutter
        • 7.2.2.4. Others
      • 7.2.3. Global Heparin Sodium Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
    • 7.3. Global Heparin Sodium (Volume)
      • 7.3.1. Global Heparin Sodium by: Type (Volume)
        • 7.3.1.1. Unfractionated Heparin
        • 7.3.1.2. Low Molecular Weight Heparin
        • 7.3.1.3. Modified Heparin
        • 7.3.1.4. Heparinoids
      • 7.3.2. Global Heparin Sodium by: Application (Volume)
        • 7.3.2.1. Venous Thromboembolism
        • 7.3.2.2. Complications of Pregnancy
        • 7.3.2.3. Cardioversion of Atrial Fibrillation/Flutter
        • 7.3.2.4. Others
      • 7.3.3. Global Heparin Sodium Region
        • 7.3.3.1. South America
          • 7.3.3.1.1. Brazil
          • 7.3.3.1.2. Argentina
          • 7.3.3.1.3. Rest of South America
        • 7.3.3.2. Asia Pacific
          • 7.3.3.2.1. China
          • 7.3.3.2.2. Japan
          • 7.3.3.2.3. India
          • 7.3.3.2.4. South Korea
          • 7.3.3.2.5. Taiwan
          • 7.3.3.2.6. Australia
          • 7.3.3.2.7. Rest of Asia-Pacific
        • 7.3.3.3. Europe
          • 7.3.3.3.1. Germany
          • 7.3.3.3.2. France
          • 7.3.3.3.3. Italy
          • 7.3.3.3.4. United Kingdom
          • 7.3.3.3.5. Netherlands
          • 7.3.3.3.6. Rest of Europe
        • 7.3.3.4. MEA
          • 7.3.3.4.1. Middle East
          • 7.3.3.4.2. Africa
        • 7.3.3.5. North America
          • 7.3.3.5.1. United States
          • 7.3.3.5.2. Canada
          • 7.3.3.5.3. Mexico
    • 7.4. Global Heparin Sodium (Price)
      • 7.4.1. Global Heparin Sodium by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Heparin Sodium: by Type(USD Million)
  • Table 2. Heparin Sodium Unfractionated Heparin , by Region USD Million (2018-2023)
  • Table 3. Heparin Sodium Low Molecular Weight Heparin , by Region USD Million (2018-2023)
  • Table 4. Heparin Sodium Modified Heparin , by Region USD Million (2018-2023)
  • Table 5. Heparin Sodium Heparinoids , by Region USD Million (2018-2023)
  • Table 6. Heparin Sodium: by Application(USD Million)
  • Table 7. Heparin Sodium Venous Thromboembolism , by Region USD Million (2018-2023)
  • Table 8. Heparin Sodium Complications of Pregnancy , by Region USD Million (2018-2023)
  • Table 9. Heparin Sodium Cardioversion of Atrial Fibrillation/Flutter , by Region USD Million (2018-2023)
  • Table 10. Heparin Sodium Others , by Region USD Million (2018-2023)
  • Table 11. South America Heparin Sodium, by Country USD Million (2018-2023)
  • Table 12. South America Heparin Sodium, by Type USD Million (2018-2023)
  • Table 13. South America Heparin Sodium, by Application USD Million (2018-2023)
  • Table 14. Brazil Heparin Sodium, by Type USD Million (2018-2023)
  • Table 15. Brazil Heparin Sodium, by Application USD Million (2018-2023)
  • Table 16. Argentina Heparin Sodium, by Type USD Million (2018-2023)
  • Table 17. Argentina Heparin Sodium, by Application USD Million (2018-2023)
  • Table 18. Rest of South America Heparin Sodium, by Type USD Million (2018-2023)
  • Table 19. Rest of South America Heparin Sodium, by Application USD Million (2018-2023)
  • Table 20. Asia Pacific Heparin Sodium, by Country USD Million (2018-2023)
  • Table 21. Asia Pacific Heparin Sodium, by Type USD Million (2018-2023)
  • Table 22. Asia Pacific Heparin Sodium, by Application USD Million (2018-2023)
  • Table 23. China Heparin Sodium, by Type USD Million (2018-2023)
  • Table 24. China Heparin Sodium, by Application USD Million (2018-2023)
  • Table 25. Japan Heparin Sodium, by Type USD Million (2018-2023)
  • Table 26. Japan Heparin Sodium, by Application USD Million (2018-2023)
  • Table 27. India Heparin Sodium, by Type USD Million (2018-2023)
  • Table 28. India Heparin Sodium, by Application USD Million (2018-2023)
  • Table 29. South Korea Heparin Sodium, by Type USD Million (2018-2023)
  • Table 30. South Korea Heparin Sodium, by Application USD Million (2018-2023)
  • Table 31. Taiwan Heparin Sodium, by Type USD Million (2018-2023)
  • Table 32. Taiwan Heparin Sodium, by Application USD Million (2018-2023)
  • Table 33. Australia Heparin Sodium, by Type USD Million (2018-2023)
  • Table 34. Australia Heparin Sodium, by Application USD Million (2018-2023)
  • Table 35. Rest of Asia-Pacific Heparin Sodium, by Type USD Million (2018-2023)
  • Table 36. Rest of Asia-Pacific Heparin Sodium, by Application USD Million (2018-2023)
  • Table 37. Europe Heparin Sodium, by Country USD Million (2018-2023)
  • Table 38. Europe Heparin Sodium, by Type USD Million (2018-2023)
  • Table 39. Europe Heparin Sodium, by Application USD Million (2018-2023)
  • Table 40. Germany Heparin Sodium, by Type USD Million (2018-2023)
  • Table 41. Germany Heparin Sodium, by Application USD Million (2018-2023)
  • Table 42. France Heparin Sodium, by Type USD Million (2018-2023)
  • Table 43. France Heparin Sodium, by Application USD Million (2018-2023)
  • Table 44. Italy Heparin Sodium, by Type USD Million (2018-2023)
  • Table 45. Italy Heparin Sodium, by Application USD Million (2018-2023)
  • Table 46. United Kingdom Heparin Sodium, by Type USD Million (2018-2023)
  • Table 47. United Kingdom Heparin Sodium, by Application USD Million (2018-2023)
  • Table 48. Netherlands Heparin Sodium, by Type USD Million (2018-2023)
  • Table 49. Netherlands Heparin Sodium, by Application USD Million (2018-2023)
  • Table 50. Rest of Europe Heparin Sodium, by Type USD Million (2018-2023)
  • Table 51. Rest of Europe Heparin Sodium, by Application USD Million (2018-2023)
  • Table 52. MEA Heparin Sodium, by Country USD Million (2018-2023)
  • Table 53. MEA Heparin Sodium, by Type USD Million (2018-2023)
  • Table 54. MEA Heparin Sodium, by Application USD Million (2018-2023)
  • Table 55. Middle East Heparin Sodium, by Type USD Million (2018-2023)
  • Table 56. Middle East Heparin Sodium, by Application USD Million (2018-2023)
  • Table 57. Africa Heparin Sodium, by Type USD Million (2018-2023)
  • Table 58. Africa Heparin Sodium, by Application USD Million (2018-2023)
  • Table 59. North America Heparin Sodium, by Country USD Million (2018-2023)
  • Table 60. North America Heparin Sodium, by Type USD Million (2018-2023)
  • Table 61. North America Heparin Sodium, by Application USD Million (2018-2023)
  • Table 62. United States Heparin Sodium, by Type USD Million (2018-2023)
  • Table 63. United States Heparin Sodium, by Application USD Million (2018-2023)
  • Table 64. Canada Heparin Sodium, by Type USD Million (2018-2023)
  • Table 65. Canada Heparin Sodium, by Application USD Million (2018-2023)
  • Table 66. Mexico Heparin Sodium, by Type USD Million (2018-2023)
  • Table 67. Mexico Heparin Sodium, by Application USD Million (2018-2023)
  • Table 68. Heparin Sodium Sales: by Type(K Tons)
  • Table 69. Heparin Sodium Sales Unfractionated Heparin , by Region K Tons (2018-2023)
  • Table 70. Heparin Sodium Sales Low Molecular Weight Heparin , by Region K Tons (2018-2023)
  • Table 71. Heparin Sodium Sales Modified Heparin , by Region K Tons (2018-2023)
  • Table 72. Heparin Sodium Sales Heparinoids , by Region K Tons (2018-2023)
  • Table 73. Heparin Sodium Sales: by Application(K Tons)
  • Table 74. Heparin Sodium Sales Venous Thromboembolism , by Region K Tons (2018-2023)
  • Table 75. Heparin Sodium Sales Complications of Pregnancy , by Region K Tons (2018-2023)
  • Table 76. Heparin Sodium Sales Cardioversion of Atrial Fibrillation/Flutter , by Region K Tons (2018-2023)
  • Table 77. Heparin Sodium Sales Others , by Region K Tons (2018-2023)
  • Table 78. South America Heparin Sodium Sales, by Country K Tons (2018-2023)
  • Table 79. South America Heparin Sodium Sales, by Type K Tons (2018-2023)
  • Table 80. South America Heparin Sodium Sales, by Application K Tons (2018-2023)
  • Table 81. Brazil Heparin Sodium Sales, by Type K Tons (2018-2023)
  • Table 82. Brazil Heparin Sodium Sales, by Application K Tons (2018-2023)
  • Table 83. Argentina Heparin Sodium Sales, by Type K Tons (2018-2023)
  • Table 84. Argentina Heparin Sodium Sales, by Application K Tons (2018-2023)
  • Table 85. Rest of South America Heparin Sodium Sales, by Type K Tons (2018-2023)
  • Table 86. Rest of South America Heparin Sodium Sales, by Application K Tons (2018-2023)
  • Table 87. Asia Pacific Heparin Sodium Sales, by Country K Tons (2018-2023)
  • Table 88. Asia Pacific Heparin Sodium Sales, by Type K Tons (2018-2023)
  • Table 89. Asia Pacific Heparin Sodium Sales, by Application K Tons (2018-2023)
  • Table 90. China Heparin Sodium Sales, by Type K Tons (2018-2023)
  • Table 91. China Heparin Sodium Sales, by Application K Tons (2018-2023)
  • Table 92. Japan Heparin Sodium Sales, by Type K Tons (2018-2023)
  • Table 93. Japan Heparin Sodium Sales, by Application K Tons (2018-2023)
  • Table 94. India Heparin Sodium Sales, by Type K Tons (2018-2023)
  • Table 95. India Heparin Sodium Sales, by Application K Tons (2018-2023)
  • Table 96. South Korea Heparin Sodium Sales, by Type K Tons (2018-2023)
  • Table 97. South Korea Heparin Sodium Sales, by Application K Tons (2018-2023)
  • Table 98. Taiwan Heparin Sodium Sales, by Type K Tons (2018-2023)
  • Table 99. Taiwan Heparin Sodium Sales, by Application K Tons (2018-2023)
  • Table 100. Australia Heparin Sodium Sales, by Type K Tons (2018-2023)
  • Table 101. Australia Heparin Sodium Sales, by Application K Tons (2018-2023)
  • Table 102. Rest of Asia-Pacific Heparin Sodium Sales, by Type K Tons (2018-2023)
  • Table 103. Rest of Asia-Pacific Heparin Sodium Sales, by Application K Tons (2018-2023)
  • Table 104. Europe Heparin Sodium Sales, by Country K Tons (2018-2023)
  • Table 105. Europe Heparin Sodium Sales, by Type K Tons (2018-2023)
  • Table 106. Europe Heparin Sodium Sales, by Application K Tons (2018-2023)
  • Table 107. Germany Heparin Sodium Sales, by Type K Tons (2018-2023)
  • Table 108. Germany Heparin Sodium Sales, by Application K Tons (2018-2023)
  • Table 109. France Heparin Sodium Sales, by Type K Tons (2018-2023)
  • Table 110. France Heparin Sodium Sales, by Application K Tons (2018-2023)
  • Table 111. Italy Heparin Sodium Sales, by Type K Tons (2018-2023)
  • Table 112. Italy Heparin Sodium Sales, by Application K Tons (2018-2023)
  • Table 113. United Kingdom Heparin Sodium Sales, by Type K Tons (2018-2023)
  • Table 114. United Kingdom Heparin Sodium Sales, by Application K Tons (2018-2023)
  • Table 115. Netherlands Heparin Sodium Sales, by Type K Tons (2018-2023)
  • Table 116. Netherlands Heparin Sodium Sales, by Application K Tons (2018-2023)
  • Table 117. Rest of Europe Heparin Sodium Sales, by Type K Tons (2018-2023)
  • Table 118. Rest of Europe Heparin Sodium Sales, by Application K Tons (2018-2023)
  • Table 119. MEA Heparin Sodium Sales, by Country K Tons (2018-2023)
  • Table 120. MEA Heparin Sodium Sales, by Type K Tons (2018-2023)
  • Table 121. MEA Heparin Sodium Sales, by Application K Tons (2018-2023)
  • Table 122. Middle East Heparin Sodium Sales, by Type K Tons (2018-2023)
  • Table 123. Middle East Heparin Sodium Sales, by Application K Tons (2018-2023)
  • Table 124. Africa Heparin Sodium Sales, by Type K Tons (2018-2023)
  • Table 125. Africa Heparin Sodium Sales, by Application K Tons (2018-2023)
  • Table 126. North America Heparin Sodium Sales, by Country K Tons (2018-2023)
  • Table 127. North America Heparin Sodium Sales, by Type K Tons (2018-2023)
  • Table 128. North America Heparin Sodium Sales, by Application K Tons (2018-2023)
  • Table 129. United States Heparin Sodium Sales, by Type K Tons (2018-2023)
  • Table 130. United States Heparin Sodium Sales, by Application K Tons (2018-2023)
  • Table 131. Canada Heparin Sodium Sales, by Type K Tons (2018-2023)
  • Table 132. Canada Heparin Sodium Sales, by Application K Tons (2018-2023)
  • Table 133. Mexico Heparin Sodium Sales, by Type K Tons (2018-2023)
  • Table 134. Mexico Heparin Sodium Sales, by Application K Tons (2018-2023)
  • Table 135. Heparin Sodium: by Type(USD/Units)
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Company Basic Information, Sales Area and Its Competitors
  • Table 143. Company Basic Information, Sales Area and Its Competitors
  • Table 144. Company Basic Information, Sales Area and Its Competitors
  • Table 145. Company Basic Information, Sales Area and Its Competitors
  • Table 146. Heparin Sodium: by Type(USD Million)
  • Table 147. Heparin Sodium Unfractionated Heparin , by Region USD Million (2025-2030)
  • Table 148. Heparin Sodium Low Molecular Weight Heparin , by Region USD Million (2025-2030)
  • Table 149. Heparin Sodium Modified Heparin , by Region USD Million (2025-2030)
  • Table 150. Heparin Sodium Heparinoids , by Region USD Million (2025-2030)
  • Table 151. Heparin Sodium: by Application(USD Million)
  • Table 152. Heparin Sodium Venous Thromboembolism , by Region USD Million (2025-2030)
  • Table 153. Heparin Sodium Complications of Pregnancy , by Region USD Million (2025-2030)
  • Table 154. Heparin Sodium Cardioversion of Atrial Fibrillation/Flutter , by Region USD Million (2025-2030)
  • Table 155. Heparin Sodium Others , by Region USD Million (2025-2030)
  • Table 156. South America Heparin Sodium, by Country USD Million (2025-2030)
  • Table 157. South America Heparin Sodium, by Type USD Million (2025-2030)
  • Table 158. South America Heparin Sodium, by Application USD Million (2025-2030)
  • Table 159. Brazil Heparin Sodium, by Type USD Million (2025-2030)
  • Table 160. Brazil Heparin Sodium, by Application USD Million (2025-2030)
  • Table 161. Argentina Heparin Sodium, by Type USD Million (2025-2030)
  • Table 162. Argentina Heparin Sodium, by Application USD Million (2025-2030)
  • Table 163. Rest of South America Heparin Sodium, by Type USD Million (2025-2030)
  • Table 164. Rest of South America Heparin Sodium, by Application USD Million (2025-2030)
  • Table 165. Asia Pacific Heparin Sodium, by Country USD Million (2025-2030)
  • Table 166. Asia Pacific Heparin Sodium, by Type USD Million (2025-2030)
  • Table 167. Asia Pacific Heparin Sodium, by Application USD Million (2025-2030)
  • Table 168. China Heparin Sodium, by Type USD Million (2025-2030)
  • Table 169. China Heparin Sodium, by Application USD Million (2025-2030)
  • Table 170. Japan Heparin Sodium, by Type USD Million (2025-2030)
  • Table 171. Japan Heparin Sodium, by Application USD Million (2025-2030)
  • Table 172. India Heparin Sodium, by Type USD Million (2025-2030)
  • Table 173. India Heparin Sodium, by Application USD Million (2025-2030)
  • Table 174. South Korea Heparin Sodium, by Type USD Million (2025-2030)
  • Table 175. South Korea Heparin Sodium, by Application USD Million (2025-2030)
  • Table 176. Taiwan Heparin Sodium, by Type USD Million (2025-2030)
  • Table 177. Taiwan Heparin Sodium, by Application USD Million (2025-2030)
  • Table 178. Australia Heparin Sodium, by Type USD Million (2025-2030)
  • Table 179. Australia Heparin Sodium, by Application USD Million (2025-2030)
  • Table 180. Rest of Asia-Pacific Heparin Sodium, by Type USD Million (2025-2030)
  • Table 181. Rest of Asia-Pacific Heparin Sodium, by Application USD Million (2025-2030)
  • Table 182. Europe Heparin Sodium, by Country USD Million (2025-2030)
  • Table 183. Europe Heparin Sodium, by Type USD Million (2025-2030)
  • Table 184. Europe Heparin Sodium, by Application USD Million (2025-2030)
  • Table 185. Germany Heparin Sodium, by Type USD Million (2025-2030)
  • Table 186. Germany Heparin Sodium, by Application USD Million (2025-2030)
  • Table 187. France Heparin Sodium, by Type USD Million (2025-2030)
  • Table 188. France Heparin Sodium, by Application USD Million (2025-2030)
  • Table 189. Italy Heparin Sodium, by Type USD Million (2025-2030)
  • Table 190. Italy Heparin Sodium, by Application USD Million (2025-2030)
  • Table 191. United Kingdom Heparin Sodium, by Type USD Million (2025-2030)
  • Table 192. United Kingdom Heparin Sodium, by Application USD Million (2025-2030)
  • Table 193. Netherlands Heparin Sodium, by Type USD Million (2025-2030)
  • Table 194. Netherlands Heparin Sodium, by Application USD Million (2025-2030)
  • Table 195. Rest of Europe Heparin Sodium, by Type USD Million (2025-2030)
  • Table 196. Rest of Europe Heparin Sodium, by Application USD Million (2025-2030)
  • Table 197. MEA Heparin Sodium, by Country USD Million (2025-2030)
  • Table 198. MEA Heparin Sodium, by Type USD Million (2025-2030)
  • Table 199. MEA Heparin Sodium, by Application USD Million (2025-2030)
  • Table 200. Middle East Heparin Sodium, by Type USD Million (2025-2030)
  • Table 201. Middle East Heparin Sodium, by Application USD Million (2025-2030)
  • Table 202. Africa Heparin Sodium, by Type USD Million (2025-2030)
  • Table 203. Africa Heparin Sodium, by Application USD Million (2025-2030)
  • Table 204. North America Heparin Sodium, by Country USD Million (2025-2030)
  • Table 205. North America Heparin Sodium, by Type USD Million (2025-2030)
  • Table 206. North America Heparin Sodium, by Application USD Million (2025-2030)
  • Table 207. United States Heparin Sodium, by Type USD Million (2025-2030)
  • Table 208. United States Heparin Sodium, by Application USD Million (2025-2030)
  • Table 209. Canada Heparin Sodium, by Type USD Million (2025-2030)
  • Table 210. Canada Heparin Sodium, by Application USD Million (2025-2030)
  • Table 211. Mexico Heparin Sodium, by Type USD Million (2025-2030)
  • Table 212. Mexico Heparin Sodium, by Application USD Million (2025-2030)
  • Table 213. Heparin Sodium Sales: by Type(K Tons)
  • Table 214. Heparin Sodium Sales Unfractionated Heparin , by Region K Tons (2025-2030)
  • Table 215. Heparin Sodium Sales Low Molecular Weight Heparin , by Region K Tons (2025-2030)
  • Table 216. Heparin Sodium Sales Modified Heparin , by Region K Tons (2025-2030)
  • Table 217. Heparin Sodium Sales Heparinoids , by Region K Tons (2025-2030)
  • Table 218. Heparin Sodium Sales: by Application(K Tons)
  • Table 219. Heparin Sodium Sales Venous Thromboembolism , by Region K Tons (2025-2030)
  • Table 220. Heparin Sodium Sales Complications of Pregnancy , by Region K Tons (2025-2030)
  • Table 221. Heparin Sodium Sales Cardioversion of Atrial Fibrillation/Flutter , by Region K Tons (2025-2030)
  • Table 222. Heparin Sodium Sales Others , by Region K Tons (2025-2030)
  • Table 223. South America Heparin Sodium Sales, by Country K Tons (2025-2030)
  • Table 224. South America Heparin Sodium Sales, by Type K Tons (2025-2030)
  • Table 225. South America Heparin Sodium Sales, by Application K Tons (2025-2030)
  • Table 226. Brazil Heparin Sodium Sales, by Type K Tons (2025-2030)
  • Table 227. Brazil Heparin Sodium Sales, by Application K Tons (2025-2030)
  • Table 228. Argentina Heparin Sodium Sales, by Type K Tons (2025-2030)
  • Table 229. Argentina Heparin Sodium Sales, by Application K Tons (2025-2030)
  • Table 230. Rest of South America Heparin Sodium Sales, by Type K Tons (2025-2030)
  • Table 231. Rest of South America Heparin Sodium Sales, by Application K Tons (2025-2030)
  • Table 232. Asia Pacific Heparin Sodium Sales, by Country K Tons (2025-2030)
  • Table 233. Asia Pacific Heparin Sodium Sales, by Type K Tons (2025-2030)
  • Table 234. Asia Pacific Heparin Sodium Sales, by Application K Tons (2025-2030)
  • Table 235. China Heparin Sodium Sales, by Type K Tons (2025-2030)
  • Table 236. China Heparin Sodium Sales, by Application K Tons (2025-2030)
  • Table 237. Japan Heparin Sodium Sales, by Type K Tons (2025-2030)
  • Table 238. Japan Heparin Sodium Sales, by Application K Tons (2025-2030)
  • Table 239. India Heparin Sodium Sales, by Type K Tons (2025-2030)
  • Table 240. India Heparin Sodium Sales, by Application K Tons (2025-2030)
  • Table 241. South Korea Heparin Sodium Sales, by Type K Tons (2025-2030)
  • Table 242. South Korea Heparin Sodium Sales, by Application K Tons (2025-2030)
  • Table 243. Taiwan Heparin Sodium Sales, by Type K Tons (2025-2030)
  • Table 244. Taiwan Heparin Sodium Sales, by Application K Tons (2025-2030)
  • Table 245. Australia Heparin Sodium Sales, by Type K Tons (2025-2030)
  • Table 246. Australia Heparin Sodium Sales, by Application K Tons (2025-2030)
  • Table 247. Rest of Asia-Pacific Heparin Sodium Sales, by Type K Tons (2025-2030)
  • Table 248. Rest of Asia-Pacific Heparin Sodium Sales, by Application K Tons (2025-2030)
  • Table 249. Europe Heparin Sodium Sales, by Country K Tons (2025-2030)
  • Table 250. Europe Heparin Sodium Sales, by Type K Tons (2025-2030)
  • Table 251. Europe Heparin Sodium Sales, by Application K Tons (2025-2030)
  • Table 252. Germany Heparin Sodium Sales, by Type K Tons (2025-2030)
  • Table 253. Germany Heparin Sodium Sales, by Application K Tons (2025-2030)
  • Table 254. France Heparin Sodium Sales, by Type K Tons (2025-2030)
  • Table 255. France Heparin Sodium Sales, by Application K Tons (2025-2030)
  • Table 256. Italy Heparin Sodium Sales, by Type K Tons (2025-2030)
  • Table 257. Italy Heparin Sodium Sales, by Application K Tons (2025-2030)
  • Table 258. United Kingdom Heparin Sodium Sales, by Type K Tons (2025-2030)
  • Table 259. United Kingdom Heparin Sodium Sales, by Application K Tons (2025-2030)
  • Table 260. Netherlands Heparin Sodium Sales, by Type K Tons (2025-2030)
  • Table 261. Netherlands Heparin Sodium Sales, by Application K Tons (2025-2030)
  • Table 262. Rest of Europe Heparin Sodium Sales, by Type K Tons (2025-2030)
  • Table 263. Rest of Europe Heparin Sodium Sales, by Application K Tons (2025-2030)
  • Table 264. MEA Heparin Sodium Sales, by Country K Tons (2025-2030)
  • Table 265. MEA Heparin Sodium Sales, by Type K Tons (2025-2030)
  • Table 266. MEA Heparin Sodium Sales, by Application K Tons (2025-2030)
  • Table 267. Middle East Heparin Sodium Sales, by Type K Tons (2025-2030)
  • Table 268. Middle East Heparin Sodium Sales, by Application K Tons (2025-2030)
  • Table 269. Africa Heparin Sodium Sales, by Type K Tons (2025-2030)
  • Table 270. Africa Heparin Sodium Sales, by Application K Tons (2025-2030)
  • Table 271. North America Heparin Sodium Sales, by Country K Tons (2025-2030)
  • Table 272. North America Heparin Sodium Sales, by Type K Tons (2025-2030)
  • Table 273. North America Heparin Sodium Sales, by Application K Tons (2025-2030)
  • Table 274. United States Heparin Sodium Sales, by Type K Tons (2025-2030)
  • Table 275. United States Heparin Sodium Sales, by Application K Tons (2025-2030)
  • Table 276. Canada Heparin Sodium Sales, by Type K Tons (2025-2030)
  • Table 277. Canada Heparin Sodium Sales, by Application K Tons (2025-2030)
  • Table 278. Mexico Heparin Sodium Sales, by Type K Tons (2025-2030)
  • Table 279. Mexico Heparin Sodium Sales, by Application K Tons (2025-2030)
  • Table 280. Heparin Sodium: by Type(USD/Units)
  • Table 281. Research Programs/Design for This Report
  • Table 282. Key Data Information from Secondary Sources
  • Table 283. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Heparin Sodium: by Type USD Million (2018-2023)
  • Figure 5. Global Heparin Sodium: by Application USD Million (2018-2023)
  • Figure 6. South America Heparin Sodium Share (%), by Country
  • Figure 7. Asia Pacific Heparin Sodium Share (%), by Country
  • Figure 8. Europe Heparin Sodium Share (%), by Country
  • Figure 9. MEA Heparin Sodium Share (%), by Country
  • Figure 10. North America Heparin Sodium Share (%), by Country
  • Figure 11. Global Heparin Sodium: by Type K Tons (2018-2023)
  • Figure 12. Global Heparin Sodium: by Application K Tons (2018-2023)
  • Figure 13. South America Heparin Sodium Share (%), by Country
  • Figure 14. Asia Pacific Heparin Sodium Share (%), by Country
  • Figure 15. Europe Heparin Sodium Share (%), by Country
  • Figure 16. MEA Heparin Sodium Share (%), by Country
  • Figure 17. North America Heparin Sodium Share (%), by Country
  • Figure 18. Global Heparin Sodium: by Type USD/Units (2018-2023)
  • Figure 19. Global Heparin Sodium share by Players 2023 (%)
  • Figure 20. Global Heparin Sodium share by Players (Top 3) 2023(%)
  • Figure 21. Global Heparin Sodium share by Players (Top 5) 2023(%)
  • Figure 22. BCG Matrix for key Companies
  • Figure 23. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 24. Pfizer Inc. (United States) Revenue: by Geography 2023
  • Figure 25. Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (China) Revenue, Net Income and Gross profit
  • Figure 26. Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (China) Revenue: by Geography 2023
  • Figure 27. Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. (China) Revenue, Net Income and Gross profit
  • Figure 28. Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. (China) Revenue: by Geography 2023
  • Figure 29. Bioiberica S.A.U. (Spain) Revenue, Net Income and Gross profit
  • Figure 30. Bioiberica S.A.U. (Spain) Revenue: by Geography 2023
  • Figure 31. OPOCRIN SPA (Italy) Revenue, Net Income and Gross profit
  • Figure 32. OPOCRIN SPA (Italy) Revenue: by Geography 2023
  • Figure 33. Yantai Dongcheng Pharmaceutical Group Co., Ltd. (China) Revenue, Net Income and Gross profit
  • Figure 34. Yantai Dongcheng Pharmaceutical Group Co., Ltd. (China) Revenue: by Geography 2023
  • Figure 35. Baxter International Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 36. Baxter International Inc. (United States) Revenue: by Geography 2023
  • Figure 37. Aspen Holdings (The Netherlands) Revenue, Net Income and Gross profit
  • Figure 38. Aspen Holdings (The Netherlands) Revenue: by Geography 2023
  • Figure 39. Sanofi-Aventis U.S. LLC (United States) Revenue, Net Income and Gross profit
  • Figure 40. Sanofi-Aventis U.S. LLC (United States) Revenue: by Geography 2023
  • Figure 41. Sichuan Deebio Pharmaceutical Co., Ltd. (China) Revenue, Net Income and Gross profit
  • Figure 42. Sichuan Deebio Pharmaceutical Co., Ltd. (China) Revenue: by Geography 2023
  • Figure 43. Global Heparin Sodium: by Type USD Million (2025-2030)
  • Figure 44. Global Heparin Sodium: by Application USD Million (2025-2030)
  • Figure 45. South America Heparin Sodium Share (%), by Country
  • Figure 46. Asia Pacific Heparin Sodium Share (%), by Country
  • Figure 47. Europe Heparin Sodium Share (%), by Country
  • Figure 48. MEA Heparin Sodium Share (%), by Country
  • Figure 49. North America Heparin Sodium Share (%), by Country
  • Figure 50. Global Heparin Sodium: by Type K Tons (2025-2030)
  • Figure 51. Global Heparin Sodium: by Application K Tons (2025-2030)
  • Figure 52. South America Heparin Sodium Share (%), by Country
  • Figure 53. Asia Pacific Heparin Sodium Share (%), by Country
  • Figure 54. Europe Heparin Sodium Share (%), by Country
  • Figure 55. MEA Heparin Sodium Share (%), by Country
  • Figure 56. North America Heparin Sodium Share (%), by Country
  • Figure 57. Global Heparin Sodium: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Pfizer Inc. (United States)
  • Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (China)
  • Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. (China)
  • Bioiberica S.A.U. (Spain)
  • OPOCRIN SPA (Italy)
  • Yantai Dongcheng Pharmaceutical Group Co., Ltd. (China)
  • Baxter International Inc. (United States)
  • Aspen Holdings (The Netherlands)
  • Sanofi-Aventis U.S. LLC (United States)
  • Sichuan Deebio Pharmaceutical Co., Ltd. (China)
Additional players considered in the study are as follows:
Yantai Dongcheng Pharmaceutical Group Co., Ltd. (China) , Changzhou Qianhong Bio-pharma Co., Ltd. (China) , Shenzhen Techdow Pharmaceutical Co., Ltd (China)
Select User Access Type

Key Highlights of Report


Mar 2024 246 Pages 76 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Heparin Sodium Market Quantitative research analysis
Global Heparin Sodium Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Heparin Sodium market are Pfizer Inc. (United States), Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (China), Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. (China), Bioiberica S.A.U. (Spain), OPOCRIN SPA (Italy), Yantai Dongcheng Pharmaceutical Group Co., Ltd. (China), Baxter International Inc. (United States), Aspen Holdings (The Netherlands), Sanofi-Aventis U.S. LLC (United States) and Sichuan Deebio Pharmaceutical Co., Ltd. (China), to name a few.
"" is seen as one of major influencing trends for Heparin Sodium Market during projected period 2023-2030.
Unfractionated Heparin segment in Global market to hold robust market share owing to "Growing incidences of thrombosis ".

Know More About Global Heparin Sodium Market Report?

Have a Query? Click Here

Other Related Reports

Low Dielectric Resin Comprehensive Study by Type (Cyanate Ester Resin, M-PPE, Fluoropolymer, Others), Application (Microelectronics, Antenna, Printed Circuit Board Industry, Other), Sales Channel (Di...
$ 3350
Glass Fibers Comprehensive Study by Type (Woven roving, Single-end roving, Multi-end roving, CSM (Chopped Strand Mat), CFM (Continuous Filament Mat), Others), End-user Industry (Transportation, Const...
$ 3750
Paste PVC Resin Comprehensive Study by Type (High K Value Grade, Medium K Value Grade, Low K Value Grade, Vinyl Acetate Copolymer Grade), Application (Automotive Sealant, Wall Paper, Synthetic Leathe...
$ 3450
Polycarbonate Comprehensive Study by Type (Phosgene, Non-Phosgene), Application (Consumer Electronics, Automotive, Construction, Optical Media, Packaging, Others), Method (Extrusion, Injection moldin...
$ 3350
Acrylic Fibers Comprehensive Study by Application (Apparels, Household furnishing, Industrial, Others), Form (Staple Fiber, Filament Fiber, Tow Fiber), Blending Type (Wool, Cotton, Cellulose, Others)...
$ 3450
Aerogel Comprehensive Study by Type (Silica, Carbon, Polymer, Others), Application (Oil & gas, Construction, Transportation (Automotive, Aerospace, Marine), Performance Coating, Day-lighting & LVHS, ...
$ 3650